Forecast

Buy	6
Hold	13
Sell	1

News Go to news feed

Boundless Bio elects two directors and confirms KPMG as auditor

At the annual general meeting, James Christensen and Jennifer Lew were elected as Class II directors; both seats run until the 2029 annual meeting. Shareholders confirmed KPMG as the independent auditor for the fiscal year ending December 31, 2026. Boundless Bio presented preclinical data on BBI‑940 and identified a kinesin target protein as a promising approach. The company also announced the early termination of its San Diego lease and will pay a lease amendment/termination fee of $10 million; the security deposit of about $0.5 million will be retained. » More on de.investing.com
Boundless Bio presents promising preclinical data for BBI-940

At the AACR annual meeting Boundless Bio presented preclinical data on BBI-940, an orally administered kinesin degrader that disrupts segregation of extrachromosomal DNA (ecDNA) in cancer cells. Studies showed that degradation of the target protein leads to missegregation, depletion of ecDNA and reduced viability of ecDNA-containing cancer cells; in vivo models demonstrated tumor regressions and antitumor activity in breast cancer models. BBI-940 is currently being evaluated in the phase 1 KOMODO-1 study in patients with advanced ER+/HER2- and TNBC-LAR. The company is focusing on ecDNA-driven tumors; the report also briefly mentioned the stock and financial metrics. » More on de.investing.com
Boundless Bio pays $10 million for early lease termination in San Diego

Boundless Bio terminated the lease for about 80,168 sq ft of lab and office space in San Diego early, effective May 31, 2026, and will pay the landlord a $10 million settlement; the posted security deposit of about $0.5 million will be retained. The termination became effective after a replacement tenant was found and is intended to ease the company’s liquidity. Additionally, Boundless Bio reported better‑than‑expected Q4 results of -$0.58 per share, launched the KOMODO‑1 Phase‑1 study for BBI‑940, and is targeting proof‑of‑concept by the second half of 2028; Leerink confirms. » More on de.investing.com

Financials

In the last quarter, Boundless Bio had revenue of 0.00€ and net profit of −20.76m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	100,00%
Net profit	−20.76m	56,10%
EBITDA	−16.83m	29,20%

Fundamentals

Metric	Value
Market capitalization	+55.64m€
Number of shares	22.47m
52-week high/low	+2,72€ - +0,82€
Dividends	No
Beta	0,38
P/E ratio	−1,01
PEG ratio	−0,85
P/B ratio	+0,98
P/S ratio	0,00

Company profile

Boundless Bio, Inc. ist ein Onkologieunternehmen in der klinischen Phase und entwickelt Krebstherapeutika, die auf den ungedeckten Bedarf von Patienten mit onkogen-amplifizierten Tumoren abzielen, indem sie extrachromosomale DNA angreifen. Der führende Produktkandidat ist BBI-355, ein oral zu verabreichender Inhibitor der Checkpoint-Kinase 1, der sich in einer klinischen Phase 1/2-Studie bei Patienten mit onkogen-amplifizierten Tumoren befindet. Das Unternehmen entwickelt außerdem BBI-825, einen oralen Inhibitor der Ribonukleotid-Reduktase, der sich in einer klinischen Phase 1/2-Studie bei Krebspatienten mit Resistenzgen-Amplifikationen befindet, sowie das ecDTx 3-Programm, das auf ein Kinesin abzielt, das am zellulären Mechanismus der Segregation von ecDNA beteiligt ist. Boundless Bio, Inc. war früher als Pretzel Therapeutics, Inc. bekannt und änderte im Juli 2019 seinen Namen in Boundless Bio, Inc. Das Unternehmen wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.